Filana Therapeutics Stock (NASDAQ:FLNA)

Financials Chart

Previous Close

$0.65

52W Range

$0.60 - $3.51

50D Avg

$0.80

200D Avg

$1.37

Market Cap

$31.79M

Avg Vol (3M)

$1.99M

Beta

-0.66

Div Yield

-

FLNA Company Profile

Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

19

IPO Date

Jul 14, 2000

Website

FLNA Performance

FLNA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-95.39M	$-141.45M	$-105.96M
Net Income	$-90.97M	$-24.34M	$-97.22M
EBITDA	$-94.45M	$-141.15M	$-105.80M
Basic EPS	$-1.88	$-0.53	$-2.32
Diluted EPS	$-1.88	$-1.46	$-2.32

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q3 18Oct 29, 18 | 4:30 AM

Q3 14Oct 30, 14 | 4:30 PM

Q2 14Aug 06, 14 | 4:30 PM